Qing Yi, MD, PhD

  • 6091 Citations
  • 45 h-Index
1991 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Personal profile

Dr. Qing Yi is a trained medical immunologist with over 25 years of experience as a well-funded and published researcher. He is one of the leading investigators in the fields of tumor immunology and immunotherapy in multiple myeloma and other cancers.

Since arriving in the US in 1998, Dr. Yi has been awarded, as the PI, 9 R01s from NCI, 1 project and 1 core grant in the MDACC Myeloma SPORE (P50), 4 R01-type translational grants from the LLS, 4 Senior Researcher Awards from the MMRF, 2 K99/R00 grants (as the mentor), and numerous intramural and industry grants. Dr. Yi and colleagues have published more than 160 peer-reviewed research articles, with 45 being in top-tier journals with an impact factor of greater than 10.

Prior to his current appointment as Associate Director of the Houston Methodist Cancer Center, Dr. Yi had faculty appointments at Lerner Research Institute at the Cleveland Clinic in Ohio, MD Anderson Cancer Center, University of Arkansas for Medical Sciences, and Karolinska Hospital and Institute, Sweden.

Research interests

For the past two decades, Dr. Yi's laboratory has been working on the following research:

(1) characterizing myeloma- and tumor-specific T cells and their subsets and examining their functions in relationship to myeloma tumor cells using both in vitro and in vivo approaches

(2) identifying novel myeloma-associated antigens and better methods for immunotherapy

(3) investigating the cross-talk between the tumor microenvironment and the immune system in malignancy

(4) clinical trials to evaluate the efficacy of immunizing patients with idiotype or dendritic cell-based vaccines

(5) exploring immunotherapies using novel myeloma antigens such as DKK1 in multiple myeloma. Our recent research focuses on (a) developing novel therapeutic monoclonal antibodies for myeloma and other cancers, (b) identifying T-cell subsets that have potent anti-tumor effects after adoptive transfer, and (c) identifying tumor microenvironment components that induce tumor drug resistance.

A commentary written by Dr. Edgar Schmitt and Dr. Tobias Bopp in J Clin Invest (122:3857-3859) comments that “During the last two decades the laboratory of Qing Yi has significantly contributed to our current understanding of potential immunotherapies in human malignancies by describing the role of DCs – and particular T cells – in multiple myeloma.”

 

Education/Academic qualification

Molecular Medicine, Postdoctoral Fellowship, Karolinska Institute

19931995

Medical Sciences, PhD, Karolinska Institute

19901993

Medicine, MB MMed, Sun Yat-sen Univ. of Med. Sciences

19831986

Medicine, MD, Jiangxi Medical College, Jiangxi, P.R. China

19781983

External positions

Professor of Cancer Biology in Medicine, Weill Cornell Medical College

Oct 1 2019 → …

Research Area Keywords

  • Cancer

Free-text keywords

  • Hematological malignancies
  • Cancer biology
  • Cancer immunotherapy
  • Myeloma

Fingerprint Dive into the research topics where Qing Yi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 25 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Role of MIF in myeloma bone homing and drug response

Yi, Q.

1/1/1912/31/21

Project: Federal Funding Agencies

A novel T-cell subset able to kill relapsed cancers

Yi, Q.

7/1/166/30/21

Project: Federal Funding Agencies

Research Output

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma

Tseng, H. C., Xiong, W., Badeti, S., Yang, Y., Ma, M., Liu, T., Ramos, C. A., Dotti, G., Fritzky, L., Jiang, J. G., Yi, Q., Guarrera, J., Zong, W. X., Liu, C. & Liu, D., Dec 1 2020, In : Nature Communications. 11, 1, 4810.

Research output: Contribution to journalArticle

Open Access
  • Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages

    Su, P., Wang, Q., Bi, E., Ma, X., Liu, L., Yang, M., Qian, J. & Yi, Q., Apr 1 2020, In : Cancer research. 80, 7, p. 1438-1450 13 p.

    Research output: Contribution to journalArticle

  • 3 Scopus citations

    Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma

    Hu, Y., Liu, H., Fang, C., Li, C., Xhyliu, F., Dysert, H., Bodo, J., Habermehl, G., Russell, B. E., Li, W., Chappell, M., Jiang, X., Ondrejka, S. L., Hsi, E. D., Maciejewski, J. P., Yi, Q., Anderson, K. C., Munshi, N. C., Ao, G., Valent, J. N. & 2 others, Lin, J. & Zhao, J., May 15 2020, In : Cancer research. 80, 10, p. 2031-2044 14 p.

    Research output: Contribution to journalArticle

  • 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice

    Wang, L., Kumar, M., Deng, Q., Wang, X., Liu, M., Gong, Z., Zhang, S., Ma, X., Xu-Monette, Z. Y., Xiao, M., Yi, Q., Young, K. H., Ramos, K. S. & Li, Y., Jan 1 2019, In : Cancer Letters. 440-441, p. 135-144 10 p.

    Research output: Contribution to journalArticle

  • 6 Scopus citations

    CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma

    Xu, R., Li, Y., Yan, H., Zhang, E., Huang, X., Chen, Q., Chen, J., Qu, J., Liu, Y., He, J., Yi, Q. & Cai, Z., Oct 14 2019, In : Cell death & disease. 10, 10, p. 781

    Research output: Contribution to journalArticle

  • 3 Scopus citations